<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283036</url>
  </required_header>
  <id_info>
    <org_study_id>L_8793</org_study_id>
    <nct_id>NCT00283036</nct_id>
  </id_info>
  <brief_title>APROVE : Irbesartan in Hypertension</brief_title>
  <official_title>Efficacy and Tolerability of Posology Adaptation of Irbesartan in Ambulatory Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study objective : To compare efficacy and tolerability of posology adaptation of Irbesartan&#xD;
      in ambulatory Hypertensive patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial Tension</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <enrollment>200</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with mild or moderate hypertension defined with arterial diastolic pressure&#xD;
             (PAD) at sit position between 90 mmHg and 110 mmHg and arterial systolic pressure&#xD;
             (PAS) at sit position between 140 mmHg and 180 mmHg.&#xD;
&#xD;
          -  Patient diagnosed after 3 consultations within 2 months who has never been under&#xD;
             treatment and responding to the required conditions for hypertension treatment with&#xD;
             irbesartan. This patient must has been under proper but insufficient hygieno dietetic&#xD;
             diet&#xD;
&#xD;
          -  Patient who has been under a none satisfied antihypertensive treatment, and for whom&#xD;
             this treatment was stopped at least 2 weeks prior to inclusion.&#xD;
&#xD;
          -  Patient with a laboratory analysis (urinary sediment- Na -K- creatinine, total&#xD;
             cholesterol) and ECG during the month prior to inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe Hypertension defined by PAS &gt; 180mmHg and/or PAD &gt; 110 mmHg.&#xD;
&#xD;
          -  Isolated systolic Hypertension&#xD;
&#xD;
          -  Secondary Hypertension&#xD;
&#xD;
          -  Arterial stenosis on unique kidney - arterial bilateral kidney stenosis&#xD;
&#xD;
          -  Non-surgically sterilized women or non-menopaused women.&#xD;
&#xD;
          -  Confirmed sodic depletion.&#xD;
&#xD;
          -  Hypersensitivity to Irbesartan.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil BENOUNICHE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Alger</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

